[cheering] [applause] Good evening everyone. I'm so excited to be with you here tonight. How many of you have ever taken a college class where you read and studied the works of 19th century Danish philosopher Saurin Kirkagar? Raise your hands. Well, I did. And nearly 40 years later, I still have no idea what the concept of existentialism means. Yes, that's right. I know. Um, but never did I think I would be on a public stage quoting him and saying his words as shared with me by a dear friend. Life can only ...

Prothena Corporation FY Conference Summary Company Overview - **Company**: Prothena Corporation (NasdaqGS:PRTA) - **Focus**: Expertise in protein dysregulation with a robust pipeline in neurodegenerative diseases, including Alzheimer's, Parkinson's, and ATTR cardiomyopathy [2][22] Key Programs and Developments - **Phase 3 Programs**: - **Prasunezumab**: Targeting early Parkinson's disease in collaboration with Roche, expected to initiate in Q4 2025 [2][22] - **Coramitug**: Targeting ATTR cardiomyopathy in collaboration with Novo, which has already initiated Phase 3 [2][22] - **Phase 2 Program**: - **PRX019**: Targeting tau in Alzheimer's disease, partnered with Bristol Myers Squibb [2][22] - **Phase 1 Program**: - **PRX012**: An undisclosed target for neurodegeneration, also partnered with Bristol [2][22] Financial Outlook - Prothena anticipates earning up to **$105 million** in clinical milestones in 2026 related to coramitug and PRX019 [2][22] Shareholder Actions - Recently approved a share repurchase program for 2026 to support distributable reserves [2][22] Pipeline Insights - **Alzheimer's Program**: The company is exploring partnerships to advance its amyloid beta program, emphasizing the importance of collaboration for cost efficiency and bandwidth [4][5] - **Transferrin Technology**: Prothena is developing PRX012, which incorporates transferrin technology to enhance blood-brain barrier penetration. Preclinical data is expected in 2026 [7][17][18] Clinical Data and Efficacy - **Amyloid Reduction**: Over **80%** of patients treated with the amyloid beta molecule are reported to be amyloid negative after 18 months [5][6] - **ARIA Rates**: Reported around **40%** for the amyloid beta treatment, with ongoing efforts to mitigate these effects [6][7] - **Coramitug Data**: Recent presentations showed a **50%** difference from placebo in NT-proBNP levels, supporting the move to Phase 3 [24][25] Collaborations and Partnerships - Prothena has established strong collaborations with Roche, Novo, and Bristol Myers Squibb, focusing on scientific dialogue and clinical decision-making [22][26] - The company is actively supporting partner programs as they transition into Phase 3 [26] Regulatory Considerations - The company is preparing for potential IND submissions, with ongoing discussions with the FDA regarding preclinical toxicology requirements [8][9] Market Position and Future Directions - Prothena is positioning itself to leverage its unique constructs in the competitive landscape of Alzheimer's treatments, particularly with its transferrin-based technology [17][40] - The company is closely monitoring developments in the field, including Eli Lilly's studies, to inform its strategic direction [5][40] Conclusion - Prothena Corporation is advancing multiple promising programs in neurodegenerative diseases, with a strong focus on collaboration and innovative technologies to enhance treatment efficacy and patient outcomes [2][22][40]

Good night everyone. My name is Sophiki and today I'll be talking to you guys about how music heals what words head. Did you feel that.Something has changed. But not only in her but also in us. This lady, she had a severe Alzheimer and she doesn't remember her family, her loved ones.She doesn't remembers nothing. But when this music starts to play, she starts to remember the movements and everything of this ballet cor choreography. And this is not magic. This is music.And on this talk, I'll be taking to you ...

Core Insights - Eisai Co., Ltd. announced new data on the anti-tau antibody etalanetug (E2814) at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, highlighting its potential in reducing tau pathology in Alzheimer's disease [1][2]. Group 1: Study Findings - The Phase Ib/II study (E2814-103) involved 7 individuals with dominantly inherited Alzheimer's disease (DIAD), showing that tau PET signals were stabilized or trended toward decrease after etalanetug administration, indicating inhibition of tau propagation [2][5]. - Etalanetug demonstrated a reduction in cerebrospinal fluid (CSF) eMTBR-tau243 by 62% at 3 months and 89% at 9 months, while plasma eMTBR-tau243 was reduced by 78% at 3 months and over 90% at 9 months, supporting its mechanism of action [5][6]. Group 2: Biomarker Development - eMTBR-tau243 is a novel biomarker that reflects tau pathology progression, with strong correlations shown between tau PET and eMTBR-tau243 in both plasma and CSF, allowing for easier measurement of tau pathology changes through blood tests [3][4][8]. - The biomarker consists of tau fragments, including tau protein amino acid residue 243, and is thought to arise during the formation of neurofibrillary tangles, a key feature of Alzheimer's disease [4][8]. Group 3: Ongoing Clinical Trials - Etalanetug is currently being evaluated in two ongoing clinical studies: the Tau NexGen Phase II/III trial in DIAD and a Phase II Study 202 for early sporadic Alzheimer's disease, both assessing etalanetug in combination with the standard-of-care antibody lecanemab [6][10]. - In September 2025, etalanetug received Fast Track designation from the U.S. FDA, indicating its potential as a disease-modifying therapy for tauopathies [10].

Core Insights - Lantheus Holdings, Inc. announced the presentation of new data on florbetaben F18 at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, scheduled for December 1-4 in San Diego, CA [1] Group 1: Presentation Details - The poster presentation will take place on December 3, 2025, from 7:15 AM to 5:30 PM PT, under session number 06 titled "Clinical Trials: Imaging" [2] - The poster is titled "Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab" and is numbered P184, presented by Marianne Chapleau from Life Molecular Imaging [2] Group 2: Product Information - Neuraceq (florbetaben F 18 injection) is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment [2] - The overall safety profile of Neuraceq is based on data from 1,090 administrations to 872 subjects, with common adverse reactions including injection site pain (3.4%), erythema (1.7%), and irritation (1.1%) [6] Group 3: Company Overview - Lantheus is a leading radiopharmaceutical-focused company that has been providing solutions for nearly 70 years, enabling the evaluation of Alzheimer's disease and other cognitive decline causes [7][8] - The company is headquartered in Massachusetts and has offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [8]

At like many other people at our school, I volunteer at Eagle Ridge Hospital. I'm in the PATH dining assistance program where my job is to mainly listen to the patients and hear what they have to say and just engage in conversation with them. I'm assigned to E2B and for those who are the same, you know, it's really not sunshine and rainbows in that ward.It usually hosts older patients. Some who stay for a couple of days, some who stay for a couple of weeks, and some who stay much longer. However, regardless ...

Raise your hand if you've ever walked into a room and forgotten why you went there. Now, keep it up just a little if you've ever panicked just for a moment, wondering whether this is how it all starts, whether this is the beginning of losing your mind. I'm Dr. . Dr.. Christine Burke, a triple board certified physician and clinical researcher, and my team and I have spent the better half of the last decade helping people with one of the most terrifying prospects we face as we age, losing our cognitive abilit ...

Health & Longevity - Women generally live longer than men globally [1] - Women are more susceptible to debilitating conditions like Alzheimer's disease [1] Research Focus - Understanding the reasons behind these differences could lead to improved aging for both sexes [1]

Group 1: Papa John's Takeover Bid - Papa John's shares rose nearly 10% after a report of a $64 per share takeover bid from Apollo Global, valuing the company at approximately $2 billion [1][2] - The stock continued to show positive movement, increasing by 3% in premarket trading [2] Group 2: Alzheimer's Diagnostic Test Approval - The U.S. FDA approved Elecsys pTau181, a blood-based biomarker test developed by Roche and Eli Lilly for initial assessment of Alzheimer's disease and cognitive decline [3][4] - This test measures phosphorylated Tau (pTau) 181 protein in human plasma, serving as a key biomarker for Alzheimer's pathology [3][4] - Elecsys pTau181 is noted to potentially reduce the need for more invasive and costly diagnostic procedures like PET and CSF testing [5] Group 3: PayPay's IPO Valuation - PayPay, Japan's leading QR code payment app, is expected to have a valuation exceeding $20 billion in its planned U.S. IPO, potentially occurring as early as December 2025 [5][6] - Investor discussions suggest a floor valuation of 2 trillion yen, with market sources indicating the final figure could surpass 3 trillion yen [6][7] - The optimism surrounding PayPay's valuation is attributed to its dominant position in Japan's digital payments market and recent profitability in SoftBank's financial segment [7]

Summary of Alpha Cognition Conference Call - October 08, 2025 Company Overview - **Company**: Alpha Cognition (NasdaqCM: ACOG) - **Lead Product**: Zunvil, approved by the FDA for mild to moderate Alzheimer's disease in Q3 2024 [2][3] Industry Context - **Target Market**: Long-term care facilities, specifically nursing homes, which represent a $2 billion opportunity for Zunvil [13][14] - **Alzheimer's Disease**: Affects memory, cognitive function, and behavior; approximately 40% of Alzheimer's patients spend their lifespan in assisted living or long-term care [4][14] Core Product Insights - **Zunvil Characteristics**: - A prodrug of galantamine, designed to minimize gastrointestinal side effects [5][6] - Demonstrates improved tolerability with less than 2% of patients reporting GI issues [11] - 0% incidence of insomnia compared to 30% for leading competitors [12] - Proven cognitive effects and functional performance, targeting behavioral symptoms common in Alzheimer's patients [12][13] Commercialization Strategy - **Launch Details**: - Launched in April 2025, generating over 1,500 prescriptions in the first quarter [3][19] - Focused on long-term care market due to high concentration of Alzheimer's patients and fewer payer restrictions [13][14] - **Sales Strategy**: - 50 salespeople targeting nursing homes and medical directors [16] - Engaged with nearly 2,000 nursing homes, with 15% writing prescriptions for Zunvil [17] - Plans for strategic partnerships with pharmacies and long-term care facilities [18] Financial Outlook - **Revenue**: Generated approximately $1.7 million in the first quarter, with expectations for steady growth [19] - **Expense Guidance**: Projected expenses between $34 to $38 million, targeting profitability by 2027 [3][20] - **Market Potential**: If Zunvil captures 10% to 25% of the market, it could generate $200 to $600 million in sales [20][31] Pipeline and Future Developments - **Additional Products**: - A sublingual formulation for patients with swallowing difficulties, expected to enter clinical studies in early 2026 [21] - A product targeting cognitive impairment from concussions, with data expected mid-next year [22] - **Market Expansion**: Plans to enter the neurology segment, representing a $1.5 billion opportunity, post achieving break-even status [25][26] Competitive Landscape - **Market Size**: The acetylcholinesterase inhibitor market is estimated at $6 to $7 billion, with historical products achieving billion-dollar sales [29][30] - **Differentiation**: Zunvil's unique formulation and tolerability profile position it as a disruptive force in the market [33] Key Takeaways - **Management Team**: Experienced team with a strong track record in drug launches [24] - **Future Focus**: Continued education for healthcare providers and strategic partnerships to enhance market penetration [33] This summary encapsulates the key points discussed during the Alpha Cognition conference call, highlighting the company's strategic direction, product differentiation, and market potential.